Opening book details…
Can I read Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials on EtoBox?
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials by Yao Neng Teo; Adriel Z. H. Ting; Yao Hao Teo; Elliot Yeung Chong; Joshua Teik Ann Tan; Nicholas L. Syn; Alys Z. Q. Chia; How Ting Ong; Alex Jia Yang Cheong; Tony Yi-Wei Li; Kian Keong Poh; Tiong Cheng Yeo; Mark Yan-Yee Chan; Raymond C. C. Wong; Ping Chai; Ching-Hui Sia is a Medicine article available to read on EtoBox.
What is Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials about?
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-hyperglycemic drugs that has been steadily increasing in popularity due to its cardiovascular and renal benefits. Dual SGLT1/SGLT2 (SGLT1/2) inhibitors have potentially augmented anti-hyperglycemic action due to additional SGLT1 inhibition. This network meta-analysis aimed to compare the treatment effect across various outcomes between pure SGLT2 inhibitors and combined SGLT1/2 inhibitors in patients with diabetes. Methodology Four electronic databases (PubMed, Embase, Cochrane, and Scopus) were searched for randomized controlled trials published from inception to 15th January 2022. Frequentist network meta-analysis was conducted to summarize the treatment effects reported in individual trials, stratified by type 1 (T1DM) and type 2 diabetes mellitus (T2DM). This metaanalysis was registered on PROSPERO (CRD42020222031). Results Our meta-analysis included 111 articles, comprising a combined cohort of 103,922 patients. SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, and luseogliflozin) and SGLT1/2 inhibitors (licogliflozin and sotagliflozin) were compared. F
Who reads Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Yao Neng Teo; Adriel Z. H. Ting; Yao Hao Teo; Elliot Yeung Chong; Joshua Teik Ann Tan; Nicholas L. Syn; Alys Z. Q. Chia; How Ting Ong; Alex Jia Yang Cheong; Tony Yi-Wei Li; Kian Keong Poh; Tiong Cheng Yeo; Mark Yan-Yee Chan; Raymond C. C. Wong; Ping Chai; Ching-Hui Sia
- Publisher
- Springer Science and Business Media LLC
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)